Related Experiment Video
Updated: Jan 10, 2026
10:24
Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report
Published on: February 12, 2018
10.7K
Twelve-Month Outcomes of Brolucizumab in Routine Clinical Practice: Fight Retinal Blindness! Registry
Trung M Dang1, Alessandro Invernizzi2,3, Vuong Nguyen2
1Eye Clinic Albury Wodonga, Albury, New South Wales, Australia.
Clinical & Experimental Ophthalmology
|November 20, 2025
Summary
Switching to brolucizumab for neovascular age-related macular degeneration (AMD) extended treatment intervals and increased disease inactivity. However, a significant portion of patients switched back, and intraocular inflammation (IOI) occurred in 9% of eyes.
Area of Science:
- Ophthalmology
- Retinal Diseases
- Pharmacological Treatments
Background:
- Neovascular age-related macular degeneration (nAMD) requires ongoing treatment.
- First-generation VEGF inhibitors often necessitate frequent injections.
- Evaluating novel treatments like brolucizumab is crucial for improving nAMD management.
Purpose of the Study:
- To assess real-world 12-month outcomes of switching nAMD patients to brolucizumab.
- To determine if brolucizumab improves disease control with fewer injections.
- To evaluate the safety and efficacy of brolucizumab in a switch scenario.
Main Methods:
- Retrospective analysis of Australian and Italian data from the Fight Retinal Blindness! registry.
- Inclusion of eyes switched to brolucizumab with at least two injections and 12-month follow-up.
- Comparison of disease activity, visual acuity, treatment intervals, and adverse events.
Main Results:
- Increased lesion inactivity from 5% to 37% (p < 0.001) after switching to brolucizumab.
- Stable visual acuity (0.6 letters change, p = 0.55).
- Extended median treatment intervals from 44 to 63 days (p < 0.001), with 30% switching back to other VEGF inhibitors.
Conclusions:
- Brolucizumab offers a clinically significant extension of treatment intervals for nAMD.
- Over a third of eyes achieved inactivity, but a notable rate of intraocular inflammation (IOI) was observed.
- Switching to brolucizumab in clinical practice shows potential for improved treatment burden but requires careful monitoring.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
938
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
938
01:28Angle Closure Glaucoma: Treatment
1.1K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.1K